Novel therapeutic agents in the treatment of metastatic colorectal cancer

Table 1 Ongoing clinical trials in Immunotherapy in colorectal cancer

Drug name	Class	Phase	ClinicalTrials.gov Identifier	Sponsor	Remarks
AMP-224	PD-1 inhibitor	1	NCT02298946	NCI	Combination with stereotactic body radiation therapy
MPDL3280A	Engineered anti-PDL1 antibody	1	NCT01375842	Genentech	Administered as single agent
Varlilumab and nivolumab	Monoclonal antibodies that binds to CD27 and PD-1	1/2	NCT02335918	Celldex therapeutics/bristol-myers squibb	Phase II to determine objective response rate
MPDL3280A and bevacizumab	Engineered anti-PDL1 antibody	1b	NCT01633970	Genentech	Assess the safety, pharmacology and preliminary efficacy of the combination
Avelumab	Antibody targeting PDL-1	1	NCT01772004	EMD serono	Open-label, dose-escalation trial
MEDI4736	Anti PDL-1	2	NCT02227667	Memorial sloan Kettering cancer center	Study to evaluate the efficacy of MEDI4736

Available from: URL: http://www.clinicaltrials.gov, accessed on 4/25/2015.